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The incidence of cholangiocarcinoma is rising. Accurate predictors of
survival at diagnosis are not well defined.
Aim
To clarify the clinical presentation and prognostic factors of intrahepatic
cholangiocarcinoma and extrahepatic cholangiocarcinoma in a contem-
porary cohort of patients.
Methods
Records for consecutive patients at the University of Michigan hospital
diagnosed with cholangiocarcinoma between January 2003 and April
2008 were reviewed.
Results
In all, 136 patients had cholangiocarcinoma (79 intra- and 57 extrahepatic
cholangiocarcinoma). Median survival was 27.3 months–25.8 months for
intrahepatic cholangiocarcinoma and 30.3 months for extrahepatic cho-
langiocarcinoma. Independent predictors of mortality at presentation on
multivariate analysis were elevated bilirubin level (HR 1.04, 95%CI 1.01–
1.07), CA 19-9 levels >100 U ⁄mL (HR 1.90, 95%CI 1.17–3.08) and stage of
disease (HR 1.51, 95%CI 1.16–1.96). After adjusting for baseline prognostic
factors, surgical therapy was associated with improved survival (HR 0.48;
95% CI 0.26–0.88). There were no significant differences regarding clinical
presentation, disease stage (P = 0.98), and survival (P = 0.51) between
intra- and extrahepatic cholangiocarcinoma.
Conclusions
Survival for cholangiocarcinoma remains poor with no significant dif-
ference in outcomes between intra- and extrahepatic cholangiocarci-
noma. Stage of disease, bilirubin level and CA 19-9 level are important
prognostic factors at presentation. Surgical therapy provides similar
efficacy for both tumours when adjusted for other prognostic variables.
Aliment Pharmacol Ther 31, 625–633
Alimentary Pharmacology & Therapeutics
ª 2010 Blackwell Publishing Ltd 625
doi:10.1111/j.1365-2036.2009.04218.x
INTRODUCTION
Cholangiocarcinoma (CCA), the second most common
primary hepatic malignancy, accounts for approxi-
mately 3% of all gastrointestinal cancers.1 It can arise
anywhere along the biliary tract and has been classi-
fied into intrahepatic cholangiocarcinoma (ICC) and
extrahepatic cholangiocarcinoma (ECC) based on its
anatomic location. ICC tumours occur proximal to the
bifurcation of the right and left hepatic ducts and are
confined to the liver. ECC tumours are further divided
into perihilar CCA, located at the bifurcation of the
hepatic ducts, and distal CCA. Perihilar tumours
account for 50–60% of all CCA, while ICC (10%) and
distal tumours (30–40%) occur less frequently.2 ICC
and ECC vary not only in location but also in epidemi-
ology, clinical presentation, prognosis and treatment
options.3
The worldwide incidence of CCA has been growing,
largely because of an increasing incidence of ICC,
while the incidence of ECC is decreasing.4 The aetiol-
ogy for the rising incidence of ICC remains unclear,
particularly given that only 10% of all CCA cases are
associated with a recognized risk factor such as pri-
mary sclerosing cholangitis (PSC), choledochal cysts,
cirrhosis and infestation with liver flukes.5 Although
analysis of the Surveillance, Epidemiology and End
Results (SEER) database suggested that underlying cir-
rhosis was the risk factor most strongly associated
with ICC when compared with randomly selected
Medicare patients without a history of cancer (OR
27.2, 95% CI 19.9–37.1),6 this epidemiologic informa-
tion is difficult to interpret as many perihilar tumours
were incorrectly classified as ICC.7, 8
For reasons of the frequent presentation of CCA with
advanced stages, prognosis continues to be poor. The
primary potential curative therapy is surgical resection,
which results in a median survival of 15–40 months
and 5-year survival rates of 9–50%.9, 10 More recently,
liver transplantation has been shown to be associated
with favourable outcomes in highly selected patients
with ECC, but confirmatory studies are necessary.11
Unfortunately, surgical therapy is feasible only in a
minority of cases.12 In patients with unresectable
tumours, optimal supportive care only provides a med-
ian survival of <1 year.13 Most studies on prognostic
factors for patients with CCA have focused on patients
undergoing surgical resection.14–16 Only a few reports
involving a small number of patients have evaluated
prognostic factors in unselected patients with CCA with
very little stratification of ICC vs. ECC.17, 18 The aims
of our study were to (i) clarify the presenting symp-
toms, treatment options, and factors affecting outcomes
of CCA and (ii) compare these findings between
patients with ICC and ECC in a contemporary consecu-
tive series of patients evaluated at a single liver referral
centre in the United States.
PATIENTS AND METHODS
Study population
We retrospectively reviewed records for consecutive
adult patients at the University of Michigan Medical
Center who had cytological or histopathological diag-
nosis of CCA between January 2003 and April 2008.
Patients were initially identified using ICD-9 codes for
CCA (155.1 and 156.1). Patients were excluded if the
suspected CCA was discovered to be ampullary, gall-
bladder, or pancreatic adenocarcinoma. Patients with-
out imaging studies were excluded given that tumour
characteristics could not otherwise be adequately
determined. All cases of CCA were defined as ICC or
ECC according to the primary tumour location. This
study was approved by the Institutional Review Board
of the University of Michigan.
Data collection
Patient demographics, clinical history, laboratory data
and imaging results were obtained through review of
computerized medical records. Age, gender, race, life-
time alcohol history and lifetime smoking history were
recorded. Alcohol use was quantified as greater or less
than 80 g of ethanol per day and tobacco use was
quantified as greater or less than 20 pack-years based
on estimates from the medical records.19 Past medical
history including any history of gallstones, liver dis-
ease including PSC and diabetes was determined by
review of clinical notes. Laboratory data including
platelets, albumin, aspartate aminotransferase, alanine
aminotransferase, alkaline phosphatase, bilirubin,
international normalized ratio, alpha-fetoprotein
(AFP), carcinoembryonic antigen (CEA) and cancer
antigen 19-9 (CA 19-9) at the time of initial diagnosis
were included in our analysis. AFP levels were also
categorized as greater or less than 8 ng ⁄ mL, the upper
limit of normal for our hospital laboratory. Tumour
characteristics were determined by imaging studies
(CT, MRI or MRCP ⁄ ERCP), which were interpreted by
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radiologists at our institution. Tumour characteristics
of interest included the CCA subtype, number of
lesions, tumour diameter, lymph node involvement,
vascular involvement, presence of extrahepatic metas-
tases, and stage of the tumour at diagnosis. Vascular
involvement was a broad category that was further
categorized as bland thrombus, vascular encasement,
or vascular invasion based on the interpretation of
available imaging studies. Tumours distal to the bifur-
cation of the right and left hepatic ducts were defined
as ECC, whereas tumours proximal to the bifurcation
were defined as ICC. Subtypes for ECC included distal,
middle and hilar tumours while subtypes for ICC
included intraductal, infiltrating, mass forming, and
mass forming + infiltrative. Staging of each lesion was
based on the American Joint Committee on Cancer
system of Tumor, Node, Metastasis (TNM) for CCA.20
Each patient’s clinical course including mode of diag-
nosis, treatments received, and survival through 31
December 2008 was recorded. Survival status of
patients not currently followed up or those patients
known to have died was verified through the Social
Security Death Index. Patient treatment was catego-
rized as the best supportive care, chemotherapy, radia-
tion therapy, chemotherapy plus radiation therapy,
resection and resection with adjuvant chemotherapy.
Statistical analysis
All data values were expressed as median (range)
unless otherwise stated. The demographic features,
tumour characteristics, treatments and survival were
compared between patients diagnosed with ICC and
ECC. Chi-squared tests were used for categorical vari-
ables and t tests were used for continuous variables.
The Scheffé method was used to adjust significance
levels in all linear regression analyses to account for
multiple comparisons. Survival curves were generated
utilizing Kaplan-Meier plots and compared using log
rank test. Cox multivariate regression analysis was
performed to determine factors associated with sur-
vival. All data analysis was performed using SPSS 15
(SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
Between January 2003 and April 2008, 131 patients
had cytological or histological confirmation of the
diagnosis of CCA in our institution. Five additional
patients were included in whom histology could not
be obtained, but clinical suspicion for CCA was suffi-
ciently high to make a presumptive diagnosis using a
combination of CT, MRI and ERCP. There were 79
(58.1%) patients diagnosed with ICC and 57 (41.9%)
patients diagnosed with ECC (Table 1). The median age
of the patients was 65 years (range 26–95). More than
90% (n = 126) of patients were Caucasian and 57%
(n = 78) were men. There was no significant difference
in the demographic features of patients with ICC and
ECC.
Laboratory values upon presentation were most
notable for a difference in bilirubin levels between
patients with ECC and those with ICC. The median bili-
rubin level was 9.4 mg ⁄ dL in those with ECC com-
pared with a median bilirubin level of 1.0 in those
with ICC (P < 0.01). The median CA 19-9 level of
140 U ⁄ mL (range 2–170 716) was not significantly dif-
ferent between patients with ICC and those with ECC
(P = 0.58). CA 19-9 levels were >100 U ⁄ mL in 38
patients (54.3%) with ICC and 29 patients (60.4%) with
ECC (P = 0.51). CEA levels were not significantly dif-
ferent between patients with ICC and those with ECC
(P = 0.62), with a median level of 2.1 ng ⁄ mL in the
entire cohort.
Chronic liver disease was found in 14.7% of all
patients, including 10 patients with cirrhosis and 10
patients with PSC. There was a trend towards a higher
prevalence of underlying liver disease in patients with
ICC (17.8%) compared with patients with ECC (10.5%),
although this was not statistically significant
(P = 0.24).
Tumour characteristics
Nearly three-fourths of patients with ECC (n = 44) pre-
sented with hilar tumours, with only 22.8% (n = 13) of
patients having nonhilar tumours. The median tumour
diameter was 6.3 cm (range 1–20) for all patients
(Table 1). Patients with ICC had larger tumours than
those with ECC, with a median tumour diameter of
7.6 cm vs. 3.0 cm, (P < 0.01). Approximately 55%
(n = 82) of patients had lymph node involvement and
nearly 20% (n = 28) had extrahepatic metastases at
diagnosis. Majority of patients had vascular encase-
ment (n = 51) with true invasion suspected in only
18% (n = 24) of patients. Less than 20% (n = 23) of
patients were diagnosed with stage I disease with
nearly 65% (n = 87) of all patients being diagnosed
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with stage III or IV disease. There was no significant
difference in the stage of disease at the time of diag-
nosis between patients with ICC and patients with ECC
(P = 0.98).
Treatment
The treatments given to patients are described in
Table 2. Approximately half (n = 64) of all patients
received some combination of chemotherapy and radi-
ation. In total, 39 (29%) patients were treated with sur-
gical resection, of which 24 (30%) patients had ICC
and 15 (26%) had ECC. There were 24% (n = 32) of
patients who were treated with best supportive care.
There was no statistically significant difference
between treatment regimens for the patients with ICC
and those with ECC, although we may have been
underpowered to detect a difference, given limited
numbers in each subgroup (P = 0.27).
Predictors of survival at time of diagnosis
The median survival of the 136 patients after diagnosis
was 27.3 months (range 0.5–312.6) with a 71% 1-year
survival and 42% 3-year survival (Figure 1). There was
no significant difference in the median survival
Table 1. Patient and tumour characteristics of patients with cholangiocarcinoma
Variable Overall (n = 136) ECC (n = 57) ICC (n = 79) P-value
Age (years)* 65 (40–83) 66 (45–79) 64 (41–83) 0.45
Gender (% males) 57.4 61.4 54.4 0.42
Race (% Caucasian) 92.7 91.2 93.7 0.24
Liver disease (%) 14.7 10.5 17.8 0.24
PSC (%) 7.4 5.3 8.9
Hepatitis C (%) 7.4 5.3 8.9
Gallstones (%) 34.6 52.6 21.5 <0.01
Alcohol >80 g ⁄ day (%) 23.5 24.6 22.8 0.81
Tobacco >20 pack-year (%) 40.4 38.6 41.8 0.71
Bilirubin (mg ⁄ dL)* 2.2 (0.3–29.1) 9.4 (0.6–23) 1.0 (0.3–22.3) <0.01
Bilirubin >3 mg ⁄ dL (%) 48.5 70.4 33.3 <0.01
Bilirubin >10 mg ⁄ dL (%) 32.8 45.6 23.4 <0.01
Platelets (K ⁄ mm3)* 265 (103–507) 274 (176–49) 254 (104–493) 0.70
Albumin (g ⁄ dL)* 3.6 (2.1–4.6) 3.6 (2.6–4.3) 3.7 (2.5–4.6) 0.19
INR* 1.0 (0.9–1.7) 1.0 (0.9–1.4) 1.0 (0.9–1.7) 0.40
AFP (ng ⁄ mL)* 3.5 (1.0–42.4) 1.8 (1.3–2.0) 3.7 (1–42.4) 0.36
CEA (ng ⁄ mL)* 2.1 (0.6–161) 2.2 (1.0–95.8) 2.1 (0.7–30) 0.62
CA 19-9 (U ⁄ mL)* 140 (2.2–68 730) 253 (7–20 358) 124 (6.5–68 730) 0.58
CA 19-9 >40 U ⁄ mL (%) 71.2 75.0 68.6 0.53
CA 19-9 >100 U ⁄ mL (%) 56.8 60.4 54.3 0.51
Number of lesions (n)* 1.0 (1–10) 1.0 (1–5) 1.0 (1–5) 0.23
Maximum diameter (cm)* 6.3 (1.5–13) 3.0 (1.5–6.8) 7.6 (3.0–13) <0.001
Abdominal lymph nodes (%) 56.9 58.9 62.0 0.72
Vascular involvement (%) 56.3 53.6 58.2 0.59
Vascular invasion (%) 17.8 12.5 21.5 0.18
Vascular encasement (%) 37.8 37.5 38.0 0.96
Extrahepatic metastases (%) 20.7 28.6 15.2 0.06
Stage, n (%)
I 23 (17.0) 6 (10.7) 17 (21.5) 0.98
II 25 (18.5) 22 (39.3) 3 (3.8)
III 59 (43.7) 12 (21.4) 47 (59.5)
IV 28 (20.7) 16 (28.6) 12 (15.9)
INR, international normalized ratio; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA 19-9, cancer antigen 19-9;
ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; PSC, primary sclerosing cholangitis.
* Expressed as median (interquartile range).
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between patients with ICC (25.8 months) and those
with ECC (30.3 months) (P = 0.51). On univariate anal-
ysis, CA 19-9 levels (P < 0.01), CEA levels (P = 0.03),
bilirubin levels (P < 0.01), albumin (P < 0.01), platelet
count (P < 0.01), number of lesions (P < 0.01), tumour
size (P = 0.03), lymph node involvement (P < 0.01),
metastatic disease (P < 0.01) and overall tumour stage
(P < 0.01) were predictors of survival (Table 2). On
multivariate analysis, independent predictors of worse
survival at the time of diagnosis included bilirubin
level (HR 1.04; 95% CI 1.01–1.07), CA 19-9 levels
>100 U ⁄ mL (HR 1.90; 95% CI 1.17–3.08) and overall
stage of disease (HR 1.51; 95% CI 1.16–1.96) (Table 3).
Patients with a CA 19-9 level over 100 U ⁄ mL had a
median survival of 18.2 months and a 3-year survival
rate of 26%, which was significantly lower than the
median survival of 42.9 months and a 3-year survival
of 58% in patients with CA 19-9 levels <100 U ⁄ mL
(P < 0.01; Figure 2). Higher bilirubin levels upon pre-
sentation were also significantly associated with worse
survival (P = 0.02). Patient with a bilirubin level below
3 mg ⁄ dL had a median survival of 37.7 months and a
three-year survival of 53%, compared with a median
survival of 20.2 months and a 3-year survival of 29%
in those with bilirubin levels >3 mg ⁄ dL (P < 0.01;
Figure 2).
Exploratory multivariate analysis was performed to
look for possible differences in prognostic factors
between patients with ICC and those with ECC,
although we had limited power for this post-hoc sub-
set analysis. For patients with ICC, bilirubin (P < 0.01)
and CA 19-9 (P = 0.04) remained significant predictors
of survival, while overall stage of disease had a trend
towards significance (P = 0.06). There were no other
significant prognostic factors on multivariate analysis.
For patients with ECC, stage of disease (P < 0.01)
remained significant, while CA 19-9 (P = 0.07) and
bilirubin (P = 0.07) had a trend towards significance.
On multivariate analysis, age (HR 1.04, 95% CI 1.00–
1.08, P = 0.04) and CEA (HR 1.01; 95% CI 1.00–1.02,
P < 0.01) were also significant prognostic factors for
ECC. No further prognostic factors were identified for
patients with ICC.
Impact of surgical treatment
After adjusting for prognostic factors prior to their
treatment, surgical resection was independently corre-
lated with a decrease in mortality (HR 0.48; 95% CI
Table 2. Type of treatment









Best supportive care 32 (23.7) 16 (28.6) 16 (20.2)
Chemotherapy 17 (12.6) 5 (8.9) 12 (15.2)
Radiation Therapy 7 (5.2) 4 (7.1) 3 (3.8)
Chemotherapy + radiation 40 (29.6) 16 (28.6) 24 (30.4)
Resection 23 (17.0) 6 (10.7) 17 (21.5)
Resection + adjuvant therapy 16 (11.9) 9 (16.1) 7 (8.9)
ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma.
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Figure 1. Overall survival of patients with cholangiocar-
cinoma. Patients with cholangiocarcinoma had a 71%
1-year survival and 42% 3-year survival. There was no
difference in survival between patients with intrahepatic
cholangiocarcinoma and those with extrahepatic cholan-
giocarcinoma.
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0.26–0.88). Patients who underwent surgical resection
had a median survival of 65.6 months and a 3-year
survival of 74%, compared with a median survival of
20.2 months and a 3-year survival of 29% in patients
who received nonsurgical therapy (Figure 3). Adjuvant
chemoradiation (n = 16) provided no additional sur-
vival benefit to surgical resection (HR 1.19; 95% CI
0.57–2.47). The prognostic significance of positive sur-
gical margins was not examined given that only five
of the 36 patients undergoing resection had positive
margins. Patients receiving chemoradiation had a
median survival of 29.3 months and a 36% 3-year
survival. Patients receiving best supportive care only
had a median survival of 9.3 months and a 3-year sur-
vival rate of 12.5%.
DISCUSSION
Our study of 136 consecutive patients is one of the
largest contemporary CCA cohorts of patients reported
in the US. Less than 20% of all CCA patients were
diagnosed with stage I disease and nearly 65% had
stage III or IV disease at presentation. Although
patients with ICC had significantly larger tumours,
there was no significant difference in the stage of dis-
ease between the two subgroups. The median survival
of our cohort was 27.3 months, with similar survival
in patients with ICC and those with ECC.
Only a few previous studies have evaluated sur-
vival in a large cohort contrasting ICC and ECC
patients. Most published series have reported survival
rates for select populations, such as post-operative
patients, ICC alone or ECC alone. According to the
SEER database, the five-year survival for ECC (15.1%
in 1983–1987) is significantly better than that of ICC,
which has consistently remained below 5%.21 In our
study, the median survival for patients with ECC was
30.3 months, which was not significantly different
from the median survival of 25.8 months in patients
with ICC. One possible explanation for the difference
Table 3. Univariate and multivariate analysis of predictors of survival in patients with cholangiocarcinoma
Variable
Univariate analysis Multivariate analysis
Hazard
ratio 95% CI Significance
Hazard
Ratio 95% CI Significance
Age 1.01 0.99–1.03 0.18
Gender 0.95 0.66–1.36 0.77
Race 0.51 0.71–1.43 0.98
Lifetime alcohol history 1.67 0.42–1.01 0.06
Lifetime smoking history 1.71 0.61–1.26 0.47
Gallstones 0.73 0.89–1.88 0.18
Underlying liver disease 0.73 0.77–2.15 0.33
Diabetes 0.99 0.69–1.63 0.79
CA 19-9 >100 U ⁄ mL 2.12 1.43–3.16 <0.001 1.90 1.17–3.08 .009
CEA >2 ng ⁄ mL 1.56 1.05–2.33 0.03
Albumin 0.57 0.43–0.75 <0.001
AST 1.00 1.00–1.00 0.49
Total bilirubin 1.46 1.16–1.80 0.005 1.04 1.16–1.96 .015
Platelet count 1.00 1.00–1.00 0.009
Number of lesions 1.69 1.21–2.35 0.002
Tumour size >5 cm 1.50 1.04–2.17 0.03
Lymph node involvement 1.64 1.13–2.38 0.009
Vascular involvement 1.35 0.94–1.94 0.11
Extrahepatic metastasis 2.92 1.87–4.57 <0.001
Stage of disease 1.61 1.31–1.99 <0.001 1.51 1.16–1.96 .002
ECC vs. ICC 1.12 0.79–1.62 0.51
AST, aspartate aminotransferase; CEA, carcinoembryonic antigen; ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic
cholangiocarcinoma.
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between our results and that of the SEER database
may be the misclassification of perihilar tumours as
ICC in the SEER database.7, 8 The correct classifica-
tion of all CCA patients was one of the strengths of
our study. Patients with perihilar tumours had a
trend towards worse prognosis in our cohort,
although this did not reach statistical significance.
Given that a majority of ECC are perihilar tumours
(75% in our cohort), this could have resulted in dra-
matic differences in survival data.
With a poor overall survival in CCA patients, few
studies have identified prognostic factors at the time of
initial presentation. Hyperbilirubinaemia, elevated CA
19-9, lymph node involvement and extrahepatic metas-
tases are a few of the primary factors that have been
previously correlated with poor survival.14, 16–18, 22, 23
In our cohort, significant prognostic factors at presenta-
tion included hyperbilirubinaemia, elevated CA 19-9
levels and overall stage of disease. Patients with CA 19-
9 levels >100 U ⁄ mL were nearly two times more likely
to die than patients with lower CA19-9 levels (HR 1.9;
95% CI 1.17–3.08). Similarly, hyperbilirubinaemia on
presentation was an important negative prognostic fac-
tor, with a decrease in survival by 4% for every 1 mg ⁄ dL
increase in bilirubin. Although hyperbilirubinaemia was
a poor prognostic factor in both ECC and ICC, the mech-
anism of hyperbilirubinaemia probably differs between
the two groups. Patients with ECC have hyperbilirubina-
emia caused by biliary obstruction, which may be
relieved with biliary stent placement. In contrast,
patients with ICC often have less evidence of biliary
obstruction and may have hyperbilirubinaemia related
Number at risk
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Figure 2. Overall survival in patients with cholangiocarcinoma according to independent predictors of survival at time of
diagnosis. (a) Patients with CA 19-9 levels <100 U ⁄ mL had a significantly prolonged survival as compared to patients with
CA 19-9 levels >100 U ⁄ mL. (b) Patients with bilirubin levels <3 mg ⁄ dL had significantly better survival compared to
patients with bilirubin levels >3 mg ⁄ dL. (c) Stage of disease at presentation is an independent predictor of mortality.
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to underlying hepatic dysfunction. Patient age and CEA
levels were also significant prognostic factors in
patients with ECC, although this subset analysis was
only exploratory in nature and these findings must be
confirmed in a larger cohort of ECC patients.
We also confirmed that a more favourable outcome
was seen in patients undergoing surgical resection
than those receiving nonsurgical treatment options,
including chemotherapy and ⁄ or radiation therapy.
Surgical resection was independently correlated with
improved survival even after adjustment for tumour
stage on multivariate analysis. Previously reported
5-year survival rates after surgical resection have ran-
ged from 20% to 43%.10, 24 In our cohort, patients
who underwent surgical therapy had a median survival
of 65.6 months with a 3-year survival of 74% com-
pared with patients undergoing best supportive care
who only had a median survival of 9.3 months and a
12% 3-year survival rate. Although our analysis
included current standard of care therapies, recent
advances including liver transplantation for early
stage tumours and palliative photodynamic therapy
for late stage tumours may help improve survival in
some patients.25
Although this is one of the largest cohorts of
patients with CCA outside of the SEER database, we
still had a limited number of patients with ICC and
ECC, making sub-group analysis difficult and poten-
tially underpowered. It is also important to note that
this is a single, tertiary-care institution study, which
can introduce a selection bias because of referral pat-
terns and make the results less generalizable. A third
limitation of this study is the diagnostic evaluation of
patients, the type of imaging tests performed and the
quality of the imaging varied among patients. This is
particularly true for patients who were initially evalu-
ated at another hospital and then referred to our insti-
tution for further care. We attempted to minimize this
variability between patients in part by only analysing
imaging studies that were interpreted by radiologists
at our institution. Another limitation of our study is
the retrospective design, which prevented analysis of
all previously reported risk factors and prognostic fac-
tors. Additional concerns because of the retrospective
design of our study include the accuracy of both
tumour staging and clinical factors, such as quantifi-
cation of alcohol and tobacco use by chart review.
Finally, the retrospective nature of this study prevents
full adjustment for all confounders. Although the stage
of disease was adjusted when assessing the prognostic
impact of surgical therapy, unmeasured confounders
such as co-morbidities that may impact a patient’s eli-
gibility for surgery may have been present. Overall, we
believe that the limitations of this study are out-
weighed by its notable strengths including the large
size of our cohort, the correct classification of all CCA
and diagnostic confirmation of CCA in nearly all
cases.
In summary, the prognosis of CCA remains poor
with an overall median survival around 27.3 months.
A majority of patients present with tumours at an
advanced stage of disease when effective therapies are
currently not available. Survival is significantly better
if CCA is diagnosed at an early stage when surgical
resection is possible. Independent predictors of sur-
vival in our cohort included stage of disease upon pre-
sentation, CA 19-9 levels <100 U ⁄ mL, lower bilirubin








































Figure 3. Overall survival in
patients with cholangiocarci-
noma according to receipt of
surgical therapy. Patients who
underwent surgical resection
had a significantly prolonged
survival as compared with
patients who received non-
surgical therapy.
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significant differences between ICC and ECC regarding
stage of disease at diagnosis, treatment options and
overall survival.
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